Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Barinthus Biotherapeutics (BRNS) Receivables (2020 - 2024)

Barinthus Biotherapeutics (BRNS) has disclosed Receivables for 5 consecutive years, with $7.1 million as the latest value for Q4 2024.

  • For the quarter ending Q4 2024, Receivables rose 45.46% year-over-year to $7.1 million, compared with a TTM value of $7.1 million through Dec 2024, up 45.46%, and an annual FY2024 reading of $7.1 million, up 45.46% over the prior year.
  • Receivables was $7.1 million for Q4 2024 at Barinthus Biotherapeutics, up from $5.2 million in the prior quarter.
  • Across five years, Receivables topped out at $22.8 million in Q1 2022 and bottomed at $940000.0 in Q1 2023.
  • Average Receivables over 5 years is $6.1 million, with a median of $4.9 million recorded in 2022.
  • The sharpest move saw Receivables surged 469.3% in 2022, then tumbled 95.88% in 2023.
  • Year by year, Receivables stood at $3.2 million in 2020, then soared by 93.71% to $6.2 million in 2021, then dropped by 22.16% to $4.9 million in 2022, then grew by 0.9% to $4.9 million in 2023, then soared by 45.46% to $7.1 million in 2024.
  • Business Quant data shows Receivables for BRNS at $7.1 million in Q4 2024, $5.2 million in Q1 2024, and $4.9 million in Q4 2023.